BC Week In Review | Aug 10, 2018
Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Aug. 8 after reporting narrowing U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower...
BC Extra | Aug 8, 2018
Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Wednesday after reporting declining U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower U.S....
BC Extra | Aug 19, 2016
Top Story

FDA extends review of Sanofi's iGlarLixi

Sanofi (Euronext:SAN; NYSE:SNY) said FDA has extended a review of Type II diabetes therapy iGlarLixi , a fixed ratio combination of Adlyxin lixisenatide and Lantus insulin glargine . Sanofi said the therapy's PDUFA date is now in...
BC Extra | Apr 14, 2016
Financial News

Bavarian Nordic cancels U.S. offering, prices private placement

Bavarian Nordic A/S (CSE:BAVA) said Wednesday it would withdraw its proposed NASDAQ listing, and instead announced the pricing of a DKK664.8 million ($101.6 million) private placement through the sale of 2.8 million shares at DKK240....
BioCentury | Nov 10, 2014
Finance

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
BioCentury | Jan 6, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones ALK-Abello A/S (CSE:ALK-B) added DKK24 to DKK616 on Christmas week after FDA said its Allergenic Products Advisory Committee will meet on Jan. 28 to discuss a BLA for Ragwitek ragweed Allergy Immunotherapy Tablet...
BC Extra | Oct 23, 2013
Company News

FDA reschedules meeting for grass allergy products

Stallergenes S.A. (Euronext:GENP) and ALK-Abello A/S (CSE:ALK-B) said FDA's Allergenic Products Advisory Committee will now meet on Dec. 11-12 to discuss BLAs from the companies for two grass pollen allergy products. On Dec. 11, the...
BioCentury | Oct 14, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down $0.45 to $5.15 last week after FDA accepted for review an NDA for Bunavail buprenorphine naloxone to treat opioid dependence. The company expects a decision by...
BC Extra | Sep 5, 2013
Company News

G-BA rebuffs Lyxumia for Type II diabetes

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Type II diabetes drug Lyxumia lixisenatide from Sanofi (Euronext:SAN; NYSE:SNY) has "no additional benefit" over comparators. The assessment is in line with a...
BioCentury | Jul 1, 2013
Finance

Highlights of weekly biotech stock moves

Allergan Inc. (NYSE:AGN) fell $10.71 (12%) to $81.99 on Monday after FDA issued draft guidance on developing generic versions of Allergan's Restasis 0.05% cyclosporine ophthalmic emulsion that could lead to earlier than expected competition for...
Items per page:
1 - 10 of 62